Related references
Note: Only part of the references are listed.Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia
Jitesh D. Kawedia et al.
BLOOD (2012)
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia
C. Liu et al.
LEUKEMIA (2012)
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia
Jitesh D. Kawedia et al.
BLOOD (2011)
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials
Andrea Willer et al.
BLOOD (2011)
Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951
Barbara De Moerloose et al.
BLOOD (2010)
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis
B. Patel et al.
LEUKEMIA (2008)
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
Jianbiao Zhou et al.
BLOOD (2007)
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Albert Moghrabi et al.
BLOOD (2007)
No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol
S Igarashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Skeletal morbidity in childhood acute lymphoblastic leukaemia
JH Davies et al.
CLINICAL ENDOCRINOLOGY (2005)
Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial
CD Mitchell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Osteonecrosis:: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) -: Experiences from trial ALL-BFM 95
B Bürger et al.
PEDIATRIC BLOOD & CANCER (2005)
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations - The past, the present and recommendations for the future
VI Avramis et al.
CLINICAL PHARMACOKINETICS (2005)
Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin
AF Belgaumi et al.
CANCER (2003)
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
BC Bostrom et al.
BLOOD (2003)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study
VI Avramis et al.
BLOOD (2002)
Bony morbidity in children treated for acute lymphoblastic leukemia
AJ Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
LB Silverman et al.
BLOOD (2001)
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the children's cancer group
LA Mattano et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E-coli L-asparaginase as first exposure
C Rizzari et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
